← Back to Search

Noninvasive Brain Stimulation

tDCS for OCD in Children

N/A
Recruiting
Led By Joan Camprodon, MD, PhD, MPH
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) ≥16 (moderately severe). OCD must be determined to be the primary or co-primary diagnosis using the The Schedule for Affective Disorders and Schizophrenia for School-Age Children- Computer administered version (KSADS-COMP) based on all available information.
Child has a full-scale IQ≥85 as assessed on the Wechsler Abbreviated Scale of Intelligence® Second Edition (WASI®-II) (within 90% CI). To decrease participant burden, the WASI®-II will only be conducted in cases of suspected intellectual disability after meeting with the PI.
Must not have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up90 minutes- 30 minutes before and 30 minutes after a single 30 minute tdcs session
Awards & highlights
No Placebo-Only Group

Study Summary

This trial will test whether tDCS can help lessen OCD symptoms in children.

Eligible Conditions
  • Pediatric Mental Health Disorder
  • Obsessive-Compulsive Disorder

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 minutes- 30 minutes before and 30 minutes after a single 30 minute tdcs session
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 minutes- 30 minutes before and 30 minutes after a single 30 minute tdcs session for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Fear Extinction Recall Task
Change in Sequential Spaceship Task
Change in Stop Signal Task
Secondary outcome measures
Change in EEG readings

Side effects data

From 2021 Phase 2 & 3 trial • 160 Patients • NCT02483468
2%
skin irritation
2%
Car accident
100%
80%
60%
40%
20%
0%
Study treatment Arm
tDCS (Active)
tDCS (Sham)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Inhibitory Control/ Goal-Orientated vs Habit-Based BehaviorExperimental Treatment1 Intervention
This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Goal-Orientated versus Habit-Based Behavior. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
Group II: Inhibitory Control/ Fear ExtinctionExperimental Treatment1 Intervention
This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Fear Extinction. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Direct Current Stimulation
2014
Completed Phase 3
~1100

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,862 Previous Clinical Trials
13,150,021 Total Patients Enrolled
Joan Camprodon, MD, PhD, MPHPrincipal InvestigatorMassachusetts General Hospital
5 Previous Clinical Trials
948 Total Patients Enrolled
Daniel Geller, MDPrincipal InvestigatorMassachusetts General Hospital

Media Library

Transcranial Direct Current Stimulation (tDCS) (Noninvasive Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT04548609 — N/A
Mental Health Disorder Research Study Groups: Inhibitory Control/ Fear Extinction, Inhibitory Control/ Goal-Orientated vs Habit-Based Behavior
Mental Health Disorder Clinical Trial 2023: Transcranial Direct Current Stimulation (tDCS) Highlights & Side Effects. Trial Name: NCT04548609 — N/A
Transcranial Direct Current Stimulation (tDCS) (Noninvasive Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04548609 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What characteristics make a patient eligible for this clinical investigation?

"For this medical investigation, 36 outpatients aged 10 to 17 with a WASI-II IQ of at least 85 and who are suffering from obsessive compulsive disorder will be accepted. In cases where intellectual disability is suspected, the PI may administer an additional WASI-II test in order to reduce participant strain."

Answered by AI

Is recruitment for this research endeavor still open?

"Affirmative. The information hosted on clinicaltrials.gov reveals that this study is recruiting. It was initially posted on January 25th 2021 and the most recent update occurred on July 21st 2022. This trial requires 36 participants from a single medical center to be enrolled in order for it to move ahead with research plans."

Answered by AI

Are individuals aged 55 and above eligible for enrollment in this trial?

"This research project is open to participants whose age ranges from 10 years old and under 17."

Answered by AI

How many participants are currently enlisted in this clinical trial?

"Affirmative, clinicaltrials.gov confirms that recruitment for this experiment is in progress. This trial was published on January 25th 2021 and most recently updated July 21st 2022 with the goal of recruiting 36 participants from one medical centre."

Answered by AI
~3 spots leftby Mar 2024